ClinicalTrials.gg
Not yet recruitingNCT07938671Updated Nov 16, 2026

Intertransverse Process Block Versus Transversus Abdominis Plane Block After Robot, Laparoscopic Hepatectomy

An interventional study of Ultrasound-Guided Bilateral Intertransverse Process Block and Ultrasound-Guided Bilateral Oblique Subcostal TAP Block Plus Rectus Sheath Block in Postoperative Pain, sponsored by Yonsei University. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Yonsei University · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Pain, Postoperative by Yonsei University — 2 open to participants now, 2 under way, none of them phase 3. Pain, Postoperative · Yonsei University.

Planned enrollment
11th of 15
64 · median 79
Started
2026
with 1 other
No phase
13 of 15
2 open now
Registered
15th of 15
by date

Among the 15 studies in Pain, Postoperative by Yonsei University, this one is the 11th largest by planned enrollment, is one of 2 that started in 2026, is one of 13 with no phase, and was the 15th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 15 studies in Pain, Postoperative by Yonsei University are open now. Recruiting first, the newest first:

All 2 open studies →

Where they have run

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pain, Postoperative by Yonsei University, or all of them as a file.
02

Study summary

This prospective randomized controlled study will compare the postoperative analgesic efficacy and opioid-sparing effect of ultrasound-guided bilateral intertransverse process block (ITPB) with bilateral transversus abdominis plane (TAP) block combined with rectus sheath block in adults undergoing elective robotic or laparoscopic hepatectomy. A total of 64 participants will be randomly assigned in a 1:1 ratio to the ITPB group or the TAP block group. Both groups will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. The primary outcome is cumulative opioid consumption during the first 24 hours after surgery, expressed as intravenous morphine equivalents. Secondary outcomes include cumulative opioid consumption through 72 hours, incisional and visceral pain intensity, shoulder pain, sensory block distribution, rescue analgesic use, quality of recovery, postoperative recovery parameters, and adverse events.

Read the detailed description

Eligible adults scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia will be screened according to the predefined inclusion and exclusion criteria. After written informed consent is obtained, participants will receive preoperative education regarding pain assessment and patient-controlled analgesia and will complete the baseline Quality of Recovery-15 assessment.

On the day of surgery, participants will be randomly assigned in a 1:1 ratio using a computer-generated randomization sequence with allocation concealed using sealed opaque envelopes.

Before induction of general anesthesia, the assigned regional block will be performed under mild sedation and real-time ultrasound guidance by an experienced anesthesiologist. Participants assigned to the ITPB group will receive bilateral intertransverse process block at the T6-7 and T9-10 levels. Participants assigned to the comparator group will receive bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block.

Both groups will receive 0.3% ropivacaine at four injection sites, with 15 mL administered at each site, for a total volume of 60 mL and a total dose of 180 mg. In participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.

Sensory block will be assessed using cold and pinprick testing at 5, 15, and 30 minutes after block placement. Participants, anesthesia and postoperative care providers, postoperative outcome assessors, and the statistical analyst will remain masked to treatment allocation. Because of the nature of the procedure, the anesthesiologist performing the assigned regional block cannot be masked and will not participate in subsequent postoperative management or outcome assessment.

All participants will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. Postoperative outcomes will be assessed at 2, 4, 6, 12, 24, 48, and 72 hours after surgery and at discharge as applicable.

Blood samples will be collected at 35 minutes, 60 minutes, 90 minutes, 2 hours, 6 hours, and 25 hours after completion of the regional block.

03

Conditions studied

  • Postoperative Pain

Keywords

  • intertransverse process block
  • ITPB
  • transversus abdominis plane block
  • TAP block
  • rectus sheath block
  • robotic hepatectomy
  • laparoscopic hepatectomy
  • postoperative pain
  • opioid-sparing
  • visceral pain
  • somatic pain
  • ropivacaine
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 19 years or older. physical status I-III. Scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia.

Able to understand and use patient-controlled analgesia (PCA). Able to understand the purpose and procedures of the study and voluntarily provide written .

Exclusion criteria

Exclusion Criteria:

History of allergy to local anesthetics or study medications. Coagulopathy, defined as > 1.5 or count \< 70,000/μL, or current anticoagulant use.

Infection at the regional block site. History of chronic pain or chronic opioid use for 3 months or longer. History of drug or alcohol abuse or dependence. Severe cardiopulmonary dysfunction or neurological disease. Cognitive impairment or psychiatric disease preventing cooperation with pain assessment, including the Numerical Rating Scale (NRS).

(BMI) \< 18 or > 35 kg/m². Pregnancy or breastfeeding. Scar at the block site that interferes with ultrasound visualization or local anesthetic spread.

History of abdominal surgery.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    ITPB Group

    Participants will receive ultrasound-guided bilateral intertransverse process block at the T6-7 and T9-10 levels before induction of general anesthesia.

    Procedure: Ultrasound-Guided Bilateral Intertransverse Process Block

  • Active comparator
    TAP + Rectus Sheath Block Group

    Participants will receive ultrasound-guided bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block before induction of general anesthesia.

    Procedure: Ultrasound-Guided Bilateral Oblique Subcostal TAP Block Plus Rectus Sheath Block

Interventions

  • ProcedureUltrasound-Guided Bilateral Intertransverse Process Block

    Before induction of general anesthesia and under mild sedation, bilateral intertransverse process block will be performed under real-time ultrasound guidance at the T6-7 and T9-10 levels. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.

    Also known as: ITPB, Intertransverse Process Block

  • ProcedureUltrasound-Guided Bilateral Oblique Subcostal TAP Block Plus Rectus Sheath Block

    Before induction of general anesthesia and under mild sedation, bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block will be performed under real-time ultrasound guidance. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.

    Also known as: TAP Block, Transversus Abdominis Plane Block, Rectus Sheath Block

06

What researchers measure

Primary outcomes

  1. Cumulative Postoperative Opioid Consumption at 24 Hours

    Cumulative opioid consumption during the first 24 hours after surgery will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents and summing the converted doses.

    Time frame: From the end of surgery through 24 hours postoperatively

Secondary outcomes

  1. Cumulative Postoperative Opioid Consumption at Additional Time Points

    Cumulative postoperative opioid consumption at each specified time point will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents.

    Time frame: At 2, 4, 6, 12, 48, and 72 hours postoperatively.

  2. Incisional Pain Intensity

    Incisional or somatic pain intensity will be assessed separately using the Numeric Rating Scale (NRS).

    Time frame: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

  3. Visceral Pain Intensity

    Deep or visceral abdominal pain intensity will be assessed separately using the Numeric Rating Scale (NRS). Participants will be instructed preoperatively to distinguish deep or generalized abdominal pain from pain at the incision site.

    Time frame: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

  4. Shoulder Pain Incidence and Intensity Assessed Using the Numeric Rating Scale (NRS)

    The presence of postoperative shoulder pain associated with diaphragmatic irritation will be recorded, and its intensity will be assessed using the Numeric Rating Scale (NRS).

    Time frame: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

  5. Extent and Distribution of Sensory Block

    Sensory block will be assessed using cold and pinprick testing. The highest and lowest blocked dermatomes, the total number of blocked dermatomes, anterior and posterior spread, and the presence or absence of posterior/paravertebral sensory block will be recorded.

    Time frame: At 5, 15, and 30 minutes after completion of the regional block.

  6. Pain Intensity at Rest and During Coughing or Movement

    Pain intensity at rest and during coughing or movement will be assessed using the Numeric Rating Scale (NRS).

    Time frame: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

  7. Time to First Rescue Analgesic Request

    Time to the first request for rescue analgesia will be recorded.

    Time frame: Up to 72 hours after surgery.

  8. Frequency of Rescue Analgesic Administration

    The number of rescue analgesic administrations during the first 48 postoperative hours will be recorded.

    Time frame: During the first 48 hours postoperatively.

  9. Quality of Recovery-15 (QoR-15) Score

    Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire on postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).

    Time frame: On postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).

  10. Time to First Flatus

    The time to first postoperative flatus will be recorded.

    Time frame: From surgery until first postoperative flatus, assessed through postoperative day 3 (POD 3).

  11. Time to First Ambulation

    The time to first postoperative ambulation will be recorded.

    Time frame: From surgery until first postoperative ambulation, assessed through postoperative day 3 (POD 3).

  12. Postoperative Length of Hospital Stay

    Postoperative length of hospital stay will be recorded as the number of calendar days from the date of surgery to hospital discharge. The date of surgery will be defined as postoperative day (POD) 0.

    Time frame: From surgery through hospital discharge, an expected average of approximately 8 days.

  13. Opioid-Related Adverse Events

    The incidence of opioid-related adverse events, including nausea, vomiting, excessive sedation, respiratory depression, pruritus, urinary retention, and reduced gastrointestinal motility, will be assessed.

    Time frame: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

  14. Block-Related Complications

    The incidence of block-related complications, including pneumothorax, pleural puncture, hematoma, infection, local anesthetic systemic toxicity, nerve injury, lower-limb weakness, unintended neuraxial block, and intra-abdominal organ injury, will be assessed.

    Time frame: From regional block placement through 72 hours postoperatively.

  15. Comprehensive Complication Index (CCI)

    Postoperative complications will be assessed using the Comprehensive Complication Index (CCI) through hospital discharge.

    Time frame: At hospital discharge, an expected average of approximately 8 days after surgery.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2028, 18 months later.

Of 2,096 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 18 months is above that.

Counting every sponsor, half of 2,109 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Nov 16, 2026
StartEst.
Oct 19, 2026
Primary completionEst.
Apr 22, 2028
CompletionEst.
Sep 25, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938671
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Oct 19, 2026 (estimated)
Primary completion
Apr 22, 2028 (estimated)
Completion
Sep 25, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Bon-Nyeo Koo, Professor
Contact
KOOBN@yuhs.ac
+82-10-6208-5797

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion